Sodium-glucose cotransporter-2 inhibitors recommended for HF with reduced, mildly reduced ejection fraction
FRIDAY, April 8, 2022 (HealthDay News) — In a clinical practice guideline issued by the American College of Cardiology, the American Heart Association, and the Heart Failure Society of America and published online April 1 in the Journal of the American College of Cardiology, updated recommendations are presented for the management of heart failure.
Paul A. Heidenreich, M.D., from the Stanford University School of Medicine in California, and colleagues conducted a literature review to inform patient-centric recommendations for clinicians to prevent, diagnose, and manage patients with heart failure.
The authors note that for heart failure with reduced ejection fraction (HFrEF), guideline-directed medical therapy is composed of four medication classes, including sodium-glucose cotransporter-2 inhibitors (SGLT2is). For heart failure with mildly reduced ejection fraction, SGLT2is have a Class of Recommendation of 2a; weaker recommendations are made for angiotensin receptor-neprilysin inhibitors (ARNis), angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, mineralocorticoid receptor antagonists (MRAs), and beta-blockers (Class of Recommendation, 2b). For heart failure with preserved ejection fraction, new recommendations are made for SGLT2is (Class of Recommendation, 2a) and for MRAs and ARNis (Class of Recommendation, 2b). Patients with previous HFrEF who now have a left ventricular ejection fraction >40 percent should continue their HFrEF treatment. New recommendations for treatment have been made for amyloid heart disease. Patients with advanced heart failure should be referred to a team specializing in heart failure, which reviews management, assesses suitability for advanced therapies, and uses palliative care where consistent with the patient’s goals of care.
“There has been an increase in rigorous science assessing how best to treat symptomatic heart failure,” Heidenreich said in a statement. “With this new guideline, the writing committee hopes to inform better treatment options for a broader number of our patients with heart failure.”
Several authors disclosed financial ties to the pharmaceutical and medical device industries.
Elevated C-Reactive Protein Linked to Increased Risk for Incident Heart Failure, All-Cause Mortality 
UACR, UPCR Provide Indistinguishable Prognostic Information in CKD 
Use of SAMA, SABA Linked to Cardiovascular Events, Mortality in Asthma, COPD 
2011 to 2021 Saw Heart Failure-Related Hospitalization Rise in CKD 
GLP-1 Receptor Agonists, SGLT-2is Slow Renal Function Decline in T2D With Albuminuria .jpeg)
1997 to 2022 Saw Increase in Pediatric Hospitalizations With AKI 
Early Complications Common in Older Kidney Transplant Recipients 
Frailty Linked to Incident Cognitive Decline in Men With CKD 
